When a familiar face from the evening news shares a personal health battle, it resonates far beyond the studio lights. Maryam Moshiri, the poised BBC presenter known for delivering headlines with calm authority, has revealed she is living with a chronic form of cancer. In a candid and deeply human disclosure, Moshiri said, "I have chronic cancer but I'm not going to die." That single sentence is not just a statement of fact; it is a declaration of resilience, a refusal to be defined by a diagnosis, and an invitation for millions to understand a condition that often hides in plain sight.
What is Maryam Moshiri's diagnosis?
Moshiri was diagnosed in November 2024 with polycythaemia vera (PV), a rare type of blood cancer that develops slowly over many years. The condition causes the bone marrow to produce too many red blood cells, which thickens the blood and increases the risk of dangerous clots. It belongs to a group of disorders called myeloproliferative neoplasms, and while it is indeed a cancer, it is often described as "chronic" because many people live with it for decades under careful management.
The diagnosis came after Moshiri's general practitioner noticed irregularities in routine blood test results. What followed was a battery of confirmatory tests, including a bone marrow biopsy and genetic testing for the JAK2 mutation, which is present in nearly all cases of PV. For Moshiri, the news was both frightening and clarifying. "You hear the word cancer and your world stops for a moment," she said in a recent interview. "But then you learn that this is not a death sentence. It is a life sentence, and I intend to live it fully."
The moment of discovery: from routine check to life-changing call
Moshiri's story underscores the quiet power of routine medical care. There were no dramatic symptoms that sent her rushing to an emergency room. Instead, a standard blood panel, perhaps ordered as part of an annual physical or for an unrelated concern, revealed an elevated hematocrit level and a high platelet count. Her GP, trained to notice such patterns, referred her to a hematologist. The subsequent diagnosis was a shock, but Moshiri credits that early detection with giving her a sense of control.
"I was lucky," she emphasized. "Lucky that my doctor was thorough. Lucky that we caught it before a clot could form in my brain or my heart. That's the danger with PV, you see. The cancer itself is slow, but the complications can be sudden and severe." Her words carry a warning and a plea: do not skip your check-ups, do not ignore the numbers on your lab report.
Understanding polycythaemia vera: more than just 'thick blood'
Polycythaemia vera is often misunderstood, even within medical communities, because its symptoms can be vague and easily attributed to aging or stress. Common signs include headaches, dizziness, fatigue, itching after a warm bath, and a ruddy complexion. Some patients experience high blood pressure, blurred vision, or a burning sensation in the hands and feet. Because these symptoms are non-specific, PV can go undiagnosed for years, or be discovered incidentally, as in Moshiri's case.
The condition is caused by a mutation in the JAK2 gene, which leads to uncontrolled production of red blood cells. While PV is not inherited in a simple pattern, the mutation is acquired during a person's lifetime. It is most commonly diagnosed in people over 60, but it can occur at any age. Moshiri, who is in her 50s, fits the typical demographic, though she has been vocal about the need for awareness among younger adults as well.
How is polycythaemia vera treated?
Treatment for PV focuses on reducing the risk of blood clots and alleviating symptoms. The cornerstone is phlebotomy, a procedure similar to blood donation, which removes excess red blood cells and lowers blood viscosity. Many patients also take low-dose aspirin to reduce clotting risk. In higher-risk cases, medications such as hydroxyurea or interferon are prescribed to suppress bone marrow activity. Moshiri has not publicly detailed her exact treatment regimen, but she has mentioned undergoing regular phlebotomy and taking daily aspirin.
"The treatment is not glamorous," she said with a wry smile. "But it is effective. I feel well most days, and I am grateful for that." Her openness about the practical aspects of managing PV serves to demystify a condition that can feel abstract and frightening to patients newly diagnosed.
Living with a chronic cancer: Moshiri's message of hope
In a media landscape that often sensationalizes illness, Moshiri's approach is refreshingly grounded. She has chosen to speak publicly not for sympathy, but for education and solidarity. "I want people to understand that a cancer diagnosis does not always mean the end," she said. "There is a whole spectrum of cancer, and chronic cancers like mine are manageable. We live with them, we work, we love, we contribute. We are not dying; we are living with cancer."
This message is particularly important for patients with myeloproliferative neoplasms, who often feel isolated because their disease is rare and not widely recognized. Support groups and online communities have flourished, but public figures like Moshiri bring a new level of visibility. Her decision to continue her broadcasting career while undergoing treatment demonstrates that a chronic illness does not have to define one's identity or limit one's ambitions.
The emotional toll and the power of mindset
Moshiri acknowledges that the psychological burden can be as heavy as the physical one. "There are days when I am tired, when I worry about the future. But I have learned to focus on what I can control," she said. She credits her family, her faith, and her work with providing structure and purpose. "The newsroom is a demanding place, but it keeps me sharp. It reminds me that I am still me."
Her words echo the growing body of research on the role of mental resilience in chronic disease management. While a positive attitude is not a cure, it can improve quality of life and adherence to treatment. Moshiri is careful not to sugarcoat her experience, but she refuses to be consumed by fear. "I am not brave," she insists. "I am just doing what anyone would do: putting one foot in front of the other."
What this means for public awareness of blood cancers
Moshiri's disclosure has already sparked conversations about the importance of regular blood tests and the need for more research into myeloproliferative neoplasms. Organizations such as the MPN Research Foundation have noted an uptick in inquiries following her announcement. "When a public figure shares their story, it gives others permission to ask questions and seek help," said a spokesperson for the foundation. "Maryam's candor is a gift to the MPN community."
For the general public, her story is a reminder that early detection can save lives, not by curing the cancer, but by preventing its most dangerous complications. A simple complete blood count (CBC) can reveal abnormalities that warrant further investigation. Moshiri urges everyone to know their numbers: "Ask your doctor what your hematocrit and platelet counts are. If they are high, ask why. You are your own best advocate."
Frequently Asked Questions
Is polycythaemia vera a terminal cancer?
No. Polycythaemia vera is a chronic, slow-growing blood cancer. With proper treatment and monitoring, many people live for decades after diagnosis. The main risk is blood clots, which can be managed with medication and phlebotomy. It is not considered a terminal illness in the same way as acute leukemias or aggressive solid tumors.
What are the early signs of polycythaemia vera?
Early signs can be subtle and include persistent headaches, fatigue, dizziness, itching after a warm shower, a flushed or red face, and high blood pressure. Some people have no symptoms at all and are diagnosed after a routine blood test shows elevated red blood cell counts.
How often should someone with PV have blood tests?
The frequency of blood tests depends on the individual's treatment plan and risk level. Typically, patients have a complete blood count every 4 to 12 weeks to monitor hematocrit and platelet levels. More frequent testing may be needed when starting a new medication or after a phlebotomy.
Can polycythaemia vera turn into acute leukemia?
In a small percentage of cases, PV can transform into acute myeloid leukemia (AML) or myelofibrosis, a more aggressive bone marrow disorder. This risk increases with age and duration of disease. Regular monitoring by a hematologist is essential to detect any changes early.
Is there a cure for polycythaemia vera?
Currently, there is no cure for PV, but it is highly treatable. The goal of therapy is to control blood counts, reduce clotting risk, and manage symptoms. Research into targeted therapies, including JAK inhibitors, offers hope for improved outcomes in the future.